June 09, 2020
Glaukos Corporation (“Glaukos”), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, has announced the pricing of its private offering of US$250 million aggregate principal amount of 2.75% Convertible Senior Notes due 2027 (the “notes”). The offering size was increased from the previously announced offering size of US$200 million aggregate principal amount of notes. The notes were offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended. Glaukos has granted to the initial purchasers of the notes a 13-day option to purchase up to an additional US$37.5 million aggregate principal amount of notes.
Latham & Watkins LLP represents the initial purchasers in the offering with a corporate deal team led by Orange County partners Shayne Kennedy, and Drew Capurro, and New York partner Witold Balaban, with Orange County associates Nicole Jazayeri and Gabrielle Masse and New York associates Marc Langer, Dian Yu and Shawn Noh. Advice was also provided on intellectual property matters by Bay Area partner Judith Hasko, with Bay Area associate Gavin Liu and New York associate Jiqiang Lin; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associate Chad Jennings and New York associate Lacey Henry; on tax matters by New York partner Elena Romanova, with New York associate Lea Li; and on compliance matters by Washington, D.C. partner Erin Brown Jones and counsel Annie Froehlich.